Angela Lopez‐Gitlitz

3.2k citations

62 papers · 1.9k indexed · 1 hit paper · h-index 14

Pulmonary and Respiratory Medicine top 1%
- Prostate Cancer Treatment and Research 60
- Prostate Cancer Diagnosis and Treatment 13
Cancer Research top 5%
- Cancer, Lipids, and Metabolism 20
Radiology, Nuclear Medicine and Imaging top 2%
- Radiopharmaceutical Chemistry and Applications 35
Endocrinology, Diabetes and Metabolism top 5%
Statistics and Probability top 5%
Oncology
- PARP inhibition in cancer therapy 9
- Cancer Treatment and Pharmacology 6
Surgery
- Management of metastatic bone disease 6
Hematology
- Multiple Myeloma Research and Treatments 5

Co-authors: Eric J. Small Matthew R. Smith Fred Saad Boris Hadaschik Julie N. Graff Stéphane Oudard David Olmos Paul N. Mainwaring
Cited by: Pulmonary and Respiratory Medicine Cancer Research Radiology, Nuclear Medicine and Imaging
Journals: Journal of Clinical Oncology (20 papers)Annals of Oncology (10 papers)The Journal of Urology (8 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Angela Lopez‐Gitlitz

60 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Angela Lopez‐Gitlitz

Since Specialization

Citations

This map shows the geographic impact of Angela Lopez‐Gitlitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Lopez‐Gitlitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Lopez‐Gitlitz more than expected).

Fields of papers citing papers by Angela Lopez‐Gitlitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Lopez‐Gitlitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Lopez‐Gitlitz. The network helps show where Angela Lopez‐Gitlitz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Angela Lopez‐Gitlitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Angela Lopez‐Gitlitz Line = papers co-authored together Angela Lopez‐Gitlitz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial European Urology Oncology ·Kim N.,Elena Castro,G. Attard,Matthew R. Smith,Shahneen Sandhu,Eleni Efstathiou,Guilhem Roubaud,Eric J. Small,Peng Gao,Dana E. Rathkopf,Marniza Saad,Howard Gurney,Wonho Jung,Won Kim,Shiva Dibaj,Daphne Wu,Jenny Zhang,Angela Lopez‐Gitlitz,Peter Francis,David Olmos	2025	1
2	Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy British Journal of Urology ·Axel S. Merseburger,Shu-Hao Yeh,Anders Bjartell,Hirotsugu Uemura,Álvaro Juárez Soto,Amitabha Bhaumik,Jürgen Böhm,Nguyen Toan Tran,Jong Won Lim,Yang Hong-hai,Suneel Mundle,Sabine Brookman‐May,Angela Lopez‐Gitlitz,Sharon McCarthy,Kim Chi,Simon Chowdhury	2024	8
3	LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE Annals of Oncology ·Emma Billmyer,Elena Castro,Gerhardt Attard,Matthew R. Smith,Shahneen Sandhu,Eleni Efstathiou,Guilhem Roubaud,Eric J. Small,S.V. FEDOSOV,Dana E. Rathkopf,Marniza Saad,Howard Gurney,Wonho Jung,Gary Mason,Shiva Dibaj,Daphne Wu,B. Diorio,Angela Lopez‐Gitlitz,Sook-An Jeoung,David Olmos	2023	6
4	1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial Annals of Oncology ·G. Attard,Shahneen Sandhu,Dana E. Rathkopf,Elena Castro,Marniza Saad,Mitchell R. Smith,Eric J. Small,David Olmos,S.V. FEDOSOV,Guilhem Roubaud,Bogdan Żurawski,Eleni Efstathiou,Daphne Wu,B. Diorio,Karen Urtishak,Umesh Singh,Yan Xu,Angela Lopez‐Gitlitz,MT Gomez Sánchez,K.N. Chi	2023	2
5	Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study Cancer Chemotherapy and Pharmacology ·Huybrecht T’jollyn,Ok,Caly Chien,Angela Lopez‐Gitlitz,Sharon McCarthy,Ярослав Павлович Шуліка,Lawrence I. Karsh,Kim Chi,Simon Chowdhury,Bansal Vibhavari,Neeraj Agarwal	2022	10
6	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease Clinical Cancer Research ·Matthew R. Smith,Shibu Thomas,Michael Gormley,Simon Chowdhury,David Olmos,Stéphane Oudard,Felix Y. Feng,Yashoda Rajpurohit,Karen Urtishak,Deborah Ricci,Brendan Rooney,Angela Lopez‐Gitlitz,Margaret K. Yu,Alexander W. Wyatt,Mark Li,Gerhardt Attard,Eric J. Small	2021	9
7	Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN European Urology ·Fred Saad,Eric J. Small,Felix Y. Feng,Julie N. Graff,David Olmos,Boris Hadaschik,Stéphane Oudard,Anil Londhe,Amitabha Bhaumik,Angela Lopez‐Gitlitz,Shibu Thomas,Suneel Mundle,Simon Chowdhury,Matthew R. Smith	2021	35
8	582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD) Annals of Oncology ·Matthew R. Smith,Shahneen Sandhu,Daniel J. George,K.N. Chi,Fred Saad,Antoine Thiery-Vuillemin,O. Ståhl,David Olmos,Daniel C. Danila,Rustem Gafanov,Elena Castro,Helen Moon,Anthony M. Joshua,Gary Mason,Byron M. Espina,Marinela Štrbac,Katherine B. Bevans,Angela Lopez‐Gitlitz,Peter Francis,Karim Fizazi	2021	1
9	Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study International Journal of Urology ·Hirotsugu Uemura,Gaku Arai,(unknown),(unknown),Hiroyoshi Suzuki,Tobias Jú Terbock,Kazuo Nishimura,Koji Fujii,Marcelle Holster,纪兴龙,Kris Deprince,Angela Lopez‐Gitlitz,Sharon McCarthy,Julie S. Larsen,Jinhui Li,Kim N.	2020	12
10	Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study BMC Urology ·Hiroji Uemura,Д А Ковалев,Yuki Iwaki,Keiichiro Imanaka,Takeshi Kambara,Angela Lopez‐Gitlitz,Alexis K. Smith,Hirotsugu Uemura	2020	2
11	Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study Prostate International ·Hiroji Uemura,Takefumi Satoh,Hideyasu Tsumura,Gaku Arai,Keiichiro Imanaka,Corrine Wells,Koji Fujii,Brendan Rooney,Angela Lopez‐Gitlitz,Byron M. Espina,HiroshiIchikawa,Eric J. Small,Matthew R. Smith	2020	17
12	Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study BMC Urology ·Hiroji Uemura,Д А Ковалев,Yuki Iwaki,Keiichiro Imanaka,Takeshi Kambara,Angela Lopez‐Gitlitz,Alexis K. Smith,Hirotsugu Uemura	2020	37
13	Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model Clinical Pharmacokinetics ·An Van den Bergh,Jan Snoeys,Loeckie De Zwart,Peter Ward,Angela Lopez‐Gitlitz,Danièle Ouellet,Mario Monshouwer,Caly Chien	2020	16
14	630P Apalutamide for non-metastatic castration resistant prostate cancer (nmCRPC): A comparison of real-life experience from an international named patient program (NPP) vs the prior phase III clinical study Annals of Oncology ·Heather Payne,Muhammad Bulbul,Konstantinos Hatzimouratidis,敏男本間,DJAR Moes,Ewen John,John McCaffrey,Giuseppe Procopio,Marniza Saad,Matteo Santoni,Ian Sayers,Thomas Schnöller,Ali El Sayed,健夫吾妻,Joris Diels,Angela Lopez‐Gitlitz,Shane McCarthy,Suneel Mundle,Adina Max,Martin Bögemann	2020	2
15	Apalutamide and Overall Survival in Prostate Cancer European Urology ·Matthew R. Smith,Fred Saad,Simon Chowdhury,Stéphane Oudard,Boris Hadaschik,Julie N. Graff,David Olmos,Paul N. Mainwaring,Ji Youl Lee,Hiroji Uemura,Peter De Porre,Alexis K. Smith,Sabine Brookman‐May,Susan Li,Ke Zhang,Brendan Rooney,Angela Lopez‐Gitlitz,Eric J. Small	2020	181
16	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Wolfgang P. Fendler,Manuel Weber,Amir Iravani,Michael S. Hofman,Jérémie Calais,Johannes Czernin,Harun Ilhan,Fred Saad,Eric J. Small,Matthew R. Smith,Antanas Burbo,Thomas A. Hope,Isabel Rauscher,Anil Londhe,Angela Lopez‐Gitlitz,Shinta Cheng,Tobias Maurer,Ken Herrmann,Matthias Eiber,Boris Hadaschik	2019	183
17	Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer Annals of Oncology ·Eric J. Small,Fred Saad,S. Chowdhury,Stéphane Oudard,Boris Hadaschik,Julie N. Graff,David Olmos,Paul N. Mainwaring,Ahmed Muhammad Al-Zubi,Hiroji Uemura,Peter De Porre,Alexis K. Smith,강문상,Angela Lopez‐Gitlitz,Matthew R. Smith	2019	99
18	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study The Lancet Oncology ·Neeraj Agarwal,Kelly McQuarrie,Anders Bjartell,Simon Chowdhury,Andrea Juliana Gomes,Byung Ha Chung,Mustafa Özgüroğlu,Álvaro Juárez Soto,Axel S. Merseburger,Hirotsugu Uemura,Dingwei Ye,Robert Given,David Cella,Ethan Basch,Branko Miladinović,Dana A. Thal,Kris Deprince,Vahid Naini,Angela Lopez‐Gitlitz,Kim N.	2019	69
19	Understanding symptomatic experience, impact, and emotional response in recently diagnosed metastatic castration-resistant prostate cancer: a qualitative study Supportive Care in Cancer ·Babith,Jason A. Randall,Mujitaba Liman Arabu,Tara Symonds,Dana A. Thal,Angela Lopez‐Gitlitz,Byron M. Espina,Kelly McQuarrie	2019	13
20	Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation Annals of Oncology ·Paul N. Mainwaring,Eric J. Small,Hiroji Uemura,Jiyoung Lee,See‐Tong Pang,Gavin Marx,Tae Gyun Kwon,Takefumi Satoh,Amitabha Bhaumik,Shinta Cheng,Anil Londhe,Angela Lopez‐Gitlitz,Matthew R. Smith	2018	4

About Angela Lopez‐Gitlitz

Angela Lopez‐Gitlitz is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research, Oncology and Hematology, having authored 62 papers that have together received 1.9k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (60 papers), Radiopharmaceutical Chemistry and Applications (35 papers), Cancer, Lipids, and Metabolism (20 papers), Prostate Cancer Diagnosis and Treatment (13 papers), PARP inhibition in cancer therapy (9 papers), Management of metastatic bone disease (6 papers), Cancer Treatment and Pharmacology (6 papers) and Multiple Myeloma Research and Treatments (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.8k citations), Cancer Research (587 citations), Radiology, Nuclear Medicine and Imaging (676 citations), Endocrinology, Diabetes and Metabolism (297 citations) and Statistics and Probability (113 citations). Angela Lopez‐Gitlitz has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Eric J. Small, Matthew R. Smith, Fred Saad, Boris Hadaschik, Julie N. Graff, Stéphane Oudard, David Olmos, Paul N. Mainwaring, Hiroji Uemura and Simon Chowdhury. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Journal of Urology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact